Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
SG RP2D was established as 10 mg/kg in Japanese patients. SG showed efficacy in Japanese patients with previously treated mTNBC, a manageable safety profile, and no new safety signals, consistent with the previous ASCENT study.
Authors
- Takanori Ishida
- Akihiko Shimomura (ORCID: https://orcid.org/0000-0002-2557-8170)
- Yutaka Yamamoto (ORCID: https://orcid.org/0000-0001-6147-6828)
- Yuki Iwahori
- Danh Huynh
- Nobuko Kawaguchi‐Sakita (ORCID: https://orcid.org/0000-0001-8667-1427)
- Danjie Zhang (ORCID: https://orcid.org/0000-0003-3968-0835)
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
- Takahiro Kogawa (ORCID: https://orcid.org/0000-0003-3730-6591)
- Norikazu Masuda (ORCID: https://orcid.org/0000-0002-7302-0278)
- Koji Matsumoto (ORCID: https://orcid.org/0000-0003-1907-0247)
- Kazuki Sudo (ORCID: https://orcid.org/0000-0002-4600-9428)
- Seigo Nakamura (ORCID: https://orcid.org/0000-0001-6597-9107)
- T. Nakayama (ORCID: https://orcid.org/0000-0002-4023-4560)
- Catherine Lai
- Dianna Gary
- Hiroji Iwata
Institutions
- Tohoku University Hospital (JP)
- National Center for Global Health and Medicine (JP)
- Kumamoto University Hospital (JP)
- Aichi Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- Gilead Sciences (United States) (US)
- National Cancer Center Hospital East (JP)
- Kyoto University Hospital (JP)
- Osaka International Cancer Institute (JP)
- Tokyo National Hospital (JP)
- SHOWA Medical University Hospital (JP)
- Hyogo Prefectural Cancer Center (JP)
- Nagoya University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1007/s10147-024-02589-x
- Citations
- 12
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Gilead Sciences